Wells David R. 4
4 · ENDRA Life Sciences Inc. · Filed Jan 6, 2021
Insider Transaction Report
Form 4
Wells David R.
Chief Financial Officer
Transactions
- Sale
Common Stock
2021-01-06$0.90/sh−34,900$31,410→ 80,003 total - Sale
Common Stock
2021-01-05$0.90/sh−100$90→ 114,903 total
Holdings
- 24,786(indirect: By StoryCorp Consulting)
Common Stock
Footnotes (1)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020.